The effect of interleukin-35 on the integrity, ICAM-1 expression and apoptosis of human aortic smooth muscle cells

Collison, 2007, The inhibitory cytokine IL-35 contributes to regulatory T-cell function, Nature, 450, 566, 10.1038/nature06306 Chaturvedi, 2011, Cutting edge: human regulatory T cells require IL-35 to mediate suppression and infectious tolerance, J Immunol, 186, 6661, 10.4049/jimmunol.1100315 Niedbala, 2007, IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells, Eur J Immunol, 37, 3021, 10.1002/eji.200737810 Kempe, 2009, Epstein-Barr virus-induced gene-3 is expressed in human atheroma plaques, Am J Pathol, 175, 440, 10.2353/ajpath.2009.080752 Lacolley, 2012, The vascular smooth muscle cell in arterial pathology: a cell that can take on multiple roles, Cardiovasc Res, 95, 194, 10.1093/cvr/cvs135 Johnson, 2014, Emerging regulators of vascular smooth muscle cell function in the development and progression of atherosclerosis, Cardiovasc Res, 103, 452, 10.1093/cvr/cvu171 Hansson, 2011, The immune system in atherosclerosis, Nat Immunol, 12, 204, 10.1038/ni.2001 Braun, 1999, Cellular adhesion molecules on vascular smooth muscle cells, Cardiovasc Res, 41, 395, 10.1016/S0008-6363(98)00302-2 Yotsui, 2007, Aspirin prevents adhesion of T lymphoblasts to vascular smooth muscle cells, FEBS Lett, 581, 427, 10.1016/j.febslet.2006.12.052 Nold-Petry, 2009, IL-32-dependent effects of IL-1beta on endothelial cell functions, Proc Natl Acad Sci USA, 106, 3883, 10.1073/pnas.0813334106 Kobayashi, 2010, Interleukin-32beta propagates vascular inflammation and exacerbates sepsis in a mouse model, PLoS One, 5, e9458, 10.1371/journal.pone.0009458 Lundberg, 2010, Innate immune signals in atherosclerosis, Clin Immunol, 134, 5, 10.1016/j.clim.2009.07.016 Murray, 1995, Human vascular smooth muscle cells poorly co-stimulate and actively inhibit allogeneic CD4+ T cell proliferation in vitro, J Immunol, 154, 151, 10.4049/jimmunol.154.1.151 Hansson, 1986, Class II MHC antigen expression in the atherosclerotic plaque: smooth muscle cells express HLA-DR, HLA-DQ and the invariant gamma chain, Clin Exp Immunol, 64, 261 Lin, 2008, Transforming growth factor beta up-regulates cysteine-rich protein 2 in vascular smooth muscle cells via activating transcription factor 2, J Biol Chem, 283, 15003, 10.1074/jbc.M801621200 Eid, 2009, Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells, Circulation, 119, 1424, 10.1161/CIRCULATIONAHA.108.827618 Collison, 2009, Regulatory T cell suppression is potentiated by target T cells in a cell contact, IL-35- and IL-10-dependent manner, J Immunol, 182, 6121, 10.4049/jimmunol.0803646 Long, 2013, IL-35 over-expression increases apoptosis sensitivity and suppresses cell growth in human cancer cells, Biochem Biophys Res Commun, 430, 364, 10.1016/j.bbrc.2012.11.004 Entwistle, 1996, HA receptors: regulators of signalling to the cytoskeleton, J Cell Biochem, 61, 569, 10.1002/(SICI)1097-4644(19960616)61:4<569::AID-JCB10>3.0.CO;2-B Maier, 2009, Thrombospondin-1-induced vascular smooth muscle cell migration is dependent on the hyaluronic acid receptor CD44, Am J Surg, 198, 664, 10.1016/j.amjsurg.2009.07.018 van de Stolpe, 1996, Intercellular adhesion molecule-1, J Mol Med (Berl), 74, 13, 10.1007/BF00202069 Bot, 2008, Hyaluronic acid: targeting immune modulatory components of the extracellular matrix in atherosclerosis, Curr Med Chem, 15, 786, 10.2174/092986708783955554 Dinarello, 2006, IL-32, a novel cytokine with a possible role in disease, Ann Rheum Dis, 65 Collison, 2012, The composition and signaling of the IL-35 receptor are unconventional, Nat Immunol, 13, 290, 10.1038/ni.2227 de Boer, 2007, Low numbers of FOXP3 positive regulatory T cells are present in all developmental stages of human atherosclerotic lesions, PLoS One, 2, e779, 10.1371/journal.pone.0000779 Kofler, 2011, Expression of circulatory dendritic cells and regulatory T-cells in patients with different subsets of coronary artery disease, J Cardiovasc Pharmacol, 57, 542, 10.1097/FJC.0b013e3182124c53 Mor, 2006, Altered status of CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes, Eur Heart J, 27, 2530, 10.1093/eurheartj/ehl222 Mor, 2007, Role of naturally occurring CD4+ CD25+ regulatory T cells in experimental atherosclerosis, Arterioscler Thromb Vasc Biol, 27, 893, 10.1161/01.ATV.0000259365.31469.89 Bjorkbacka, 2013, Emerging biomarkers and intervention targets for immune-modulation of atherosclerosis—a review of the experimental evidence, Atherosclerosis, 227, 9, 10.1016/j.atherosclerosis.2012.10.074 Chalubinski, 2013, Comprehensive insight into immune regulatory mechanisms and vascular wall determinants of atherogenesis—emerging perspectives of immunomodulation, Arch Med Sci, 9, 159, 10.5114/aoms.2013.33355